Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Yue, Dongsheng ^a,b,c   Li, Hui ^c   Che, Juanjuan ^d   Zhang, Yi ^e   Tseng, Hsin Hui K ^c   Jin, Joy Q ^c   Luh, Thomas M ^c   Giroux Leprieur, Etienne ^c   Mo, Minli ^f   Zheng, Qingfeng ^c,g   Shi, Huaiyin ^h   Zhang, Hua ^a,b   Hao, Xishan ^a,b   Wang, Changli ^a,b   Jablons, David M ^c   He, Biao ^c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f TSINGHUA UNIVERSITY   (China)

^g PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^h CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

EMT; Gli; Lung squamous cell carcinoma; Sonic Hedgehog

Indexed keywords

BETA CATENIN; RECOMBINANT PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; UVOMORULIN; VISMODEGIB;

ADULT; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG CARCINOGENESIS; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84901463458     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-34     Document Type: Article

References (36)

1. Cancer statistics. Siegel R, Ma JM, Zou ZH, Jemal A, CA Cancer J Clin 2014 64 9 29 10.3322/caac.21208 24399786
2. Pathology of lung cancer. Travis WD, Clin Chest Med 2012 32 669
3. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Drilon A, Rekhtman N, Ladanyi M, Paik P, Lancet Oncol 2012 13 418 E426 10.1016/S1470-2045(12)70291-7 23026827
4. National survey of non-small cell lung cancer in the United States: Epidemiology, pathology and patterns of care. Little AG, Gay EG, Gaspar LE, Stewart AK, Lung Cancer 2007 57 253 260 10.1016/j.lungcan.2007.03.012 17451842 (Pubitemid 47285417)
5. Regulatory networks defining EMT during cancer initiation and progression. de Craene B, Berx G, Nat Rev Cancer 2013 13 97 110 10.1038/nrc3447 23344542
6. Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells. Hong KO, Kim JH, Hong JS, Yoon HJ, Lee JI, Hong SP, Hong SD, J Exp Clin Cancer Res 2009 28 28 38 10.1186/1756-9966-28-28 19243631
7. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G, Clin Cancer Res 2008 14 7430 7437 10.1158/1078-0432.CCR- 08-0935 19010860
8. Direct regulation of TWIST by HIF-1 alpha promotes metastasis. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ, Nat Cell Biol 2008 10 295 305 10.1038/ncb1691 18297062 (Pubitemid 351331016)
9. ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. Vendrell JA, Thollet A, Nguyen NT, Ghayad SE, Vinot S, Bieche I, Grisard E, Josserand V, Coll JL, Roux P, Corbo L, Treilleux I, Rimokh R, Cohen PA, Cancer Res 2012 72 3593 3606 10.1158/0008-5472.CAN-11-3095 22593193
10. Molecular markers associated with outcome and metastasis in human pancreatic cancer. van den Broeck A, Vankelecom H, van Eijsden R, Govaere O, Topal B, J Exp Clin Cancer Res 2012 31 68 77 10.1186/1756-9966-31-68 22925330
11. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Lauth M, Bergstrom A, Shimokawa T, Toftgard R, Proc Natl Acad Sci U S A 2007 104 8455 8460 10.1073/pnas.0609699104 17494766 (Pubitemid 47175509)
12. Non-canonical activation of GLI transcription factors. Lauth M, Toftgard R, Cell Cycle 2007 6 2458 2463 10.4161/cc.6.20.4808 17726373
13. The Hedgehog pathway as a drug target in cancer therapy. Lauth M, Toftgard R, Curr Opin Investig Drugs 2007 8 457 461 17621875 (Pubitemid 46868067)
14. Frequent deregulations in the Hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Mimeault M, Batra SK, Pharmacol Rev 2010 62 497 524 10.1124/pr.109.002329 20716670
15. Small-molecule modulators of the Sonic Hedgehog signaling pathway. Stanton BZ, Peng LF, Mole Biosyst 2010 6 44 54 10.1039/b910196a
16. Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. Tostar U, Malm CJ, Meis-Kindblom JM, Kindblom LG, Toftgard R, Unden AB, J Pathol 2006 208 17 25 10.1002/path.1882 16294371 (Pubitemid 43025700)
17. Identification of an amplified, highly expressed gene in a human Glioma. Kinzler KW, Bigner SH, Bigner DD, Trent JM, Law ML, O'Brien SJ, Wong AJ, Vogelstein B, Cytogenet Cell Genet 1987 46 639 639
18. Activation of the hedgehog pathway in a subset of lung cancers. Chi SM, Huang SH, Li CX, Zhang XL, He NG, Bhutani MS, Jones D, Castro CY, Logrono R, Haque A, Zwischenberger J, Tyring SK, Zhang H, Xie J, Cancer Lett 2006 244 53 60 10.1016/j.canlet.2005.11.036 16446029 (Pubitemid 44485862)
19. Genornics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ, J Clin Oncol 2006 24 1924 1931 10.1200/JCO.2005.04.4974 16567768 (Pubitemid 46638992)
20. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M, Nature 2003 425 851 856 10.1038/nature02009 14520413 (Pubitemid 37355945)
21. Mutations in SUFU predispose to medulloblastoma. Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, Zhang X, Agatep R, Chiappa S, Gao L, Lowrance A, Hao A, Goldstein AM, Stavrou T, Scherer SW, Dura WT, Wainwright B, Squire JA, Rutka JT, Hogg D, Nat Genet 2002 31 306 310 10.1038/ng916 12068298
22. Gli as a novel therapeutic target in malignant pleural mesothelioma. Li H, Lui N, Cheng T, Tseng HHK, Yue DS, Giroux-Leprieur E, Do HT, Sheng Q, Jin JQ, Luh TW, Jablons DM, He B, PLoS One 2013 8 57346 10.1371/journal.pone.0057346 23483902
23. Activation of the hedgehog pathway in chronic myelogeneous leukemia patients. Long B, Zhu HL, Zhu CX, Liu T, Meng WT, J Exp Clin Cancer Res 2011 30 8 12 10.1186/1756-9966-30-8 21235817
24. Gli2-mediated melanoma invasion and metastasis. Alexaki VI, Javelaud D, van Kempen LCL, Mohammad KS, Dennler S, Luciani F, Hoek KS, Juàrez P, Goydos JS, Fournier PJ, Sibon C, Bertolotto C, Verrecchia F, Saule S, Delmas V, Ballotti R, Larue L, Saiag P, Guise TA, Mauviel A, J Natl Cancer Inst 2010 102 1148 1159 10.1093/jnci/djq257 20660365
25. GLI1 modulates EMT in pancreatic cancer-letter. Inaguma S, Kasai K, Hashimoto M, Ikeda H, Cancer Res 2012 72 3702 3703 10.1158/0008-5472.CAN-12-0379 22761339
26. GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. Joost S, Almada LL, Rohnalter V, Holz PS, Vrabel AM, Fernandez-Barrena MG, McWilliams RR, Krause M, Fernandez-Zapico ME, Lauth M, Cancer Res 2012 72 88 99 10.1158/0008-5472.CAN-10-4621 22086851
27. Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Yuan Z, Goetz JA, Singh S, Ogden SK, Petty WJ, Black CC, Memoli VA, Dmitrovsky E, Robbins DJ, Oncogene 2007 26 1046 1055 10.1038/sj.onc.1209860 16909105
28. Targeting Gli transcription activation by small molecule suppresses tumor growth. Bosco-Clement G, Zhang F, Chen Z, Zhou HM, Li H, Mikami I, Hirata T, Yagui-Beltran A, Lui N, Do HT, Cheng T, Tseng HH, Choi H, Fang LT, Kim IJ, Yue D, Wang C, Zheng Q, Fujii N, Mann M, Jablons DM, He B, Oncogene 2013 33 2087 2097 23686308
29. Overexpression of hedgehog pathway molecules and FOXM1 in non-small cell lung carcinomas. Gialmanidis IP, Bravou V, Amanetopoulou SG, Varakis J, Kourea H, Papadaki H, Lung Cancer 2009 6 66 64 74
30. Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer. Raz G, Allen KE, Kingsley C, Cherni I, Arora S, Watanabe A, Lorenzo CD, Edwards VDK, Sridhar S, Hostetter G, Weiss GJ, Lung Cancer 2012 76 191 196 10.1016/j.lungcan.2011.10.015 22115706
31. Unveiling the role of nuclear transport in epithelial-to-mesenchymal transition. Azmi AS, Curr Cancer Drug Targets 2013 13 906 914 10.2174/15680096113136660096 24168192
32. The Hedgehog's tale: developing strategies for targeting cancer. Ng JMY, Curran T, Nat Rev Cancer 2011 11 493 501 10.1038/nrc3079 21614026
33. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD, Clin Cancer Res 2011 7 2502 2511
34. Efficacy and safety of Vismodegib in advanced basal-cell carcinoma. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A, N Engl J Med 2012 366 2171 2179 10.1056/NEJMoa1113713 22670903
35. Vismodegib. Dlugosz A, Agrawal S, Kirkpatrick P, Nat Rev Drug Discov 2012 11 437 438 10.1038/nrd3753 22653209
36. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand? Agarwal V, Lind MJ, Cawkwell L, Cancer Treat Rev 2011 37 533 542 10.1016/j.ctrv.2010.11.004 21183281